Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights
09:01pm, Monday, 15'th Nov 2021 Intrado Digital Media
Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
06:29pm, Monday, 15'th Nov 2021
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation: Fortress Biotech Subsidiary Files For IPO
07:31am, Friday, 29'th Oct 2021
Journey Medical Corporation: Fortress Biotech Subsidiary Files For IPO
Fortress Biotech to Participate in Dawson James Securities' 6th Annual Small Cap Growth Conference
08:30am, Monday, 18'th Oct 2021
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or mone
FBIO Stock: Why It Increased This Week
11:33am, Thursday, 14'th Oct 2021
The stock price of Fortress Biotech (NASDAQ: FBIO) increased by over 6% this past week. This is why it happened.
NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its li
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
12:17pm, Monday, 11'th Oct 2021
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
08:00am, Wednesday, 06'th Oct 2021
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer
08:30am, Tuesday, 05'th Oct 2021
NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focus
FBIO Stock: Why It Increased Today
12:38pm, Wednesday, 29'th Sep 2021
The stock price of Fortress Biotech (NASDAQ: FBIO) increased by over 4% today. This is why it happened.
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1
Fortress Biotech to Participate in Three September 2021 Investor Conferences
08:30am, Thursday, 09'th Sep 2021
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or mon
Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates
06:18pm, Monday, 16'th Aug 2021
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 71.43% and 29.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights
04:01pm, Monday, 16'th Aug 2021
Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record
